Ranbaxy ends last trading day on bright note; surges over 5%

Image
Press Trust of India Mumbai
Last Updated : Apr 01 2015 | 7:07 PM IST
Shares of Ranbaxy Laboratories today ended with strong gains on the last day of its trade, as the company is being merged with Sun Pharmaceutical in a USD 4 billion deal.
Shares of Ranbaxy Laboratories gained 5.63 per cent to end at Rs 859.90 on the BSE. During the day, it soared 6.74 per cent to Rs 869 -- its 52-week high.
Sun Pharmaceutical Industries also rose by 5.51 per cent to settle at Rs 1,078.55. The stock was the top gainer among the 30-Sensex scrips.
Today was the last trading session for shares of Ranbaxy as domestic indices are closed tomorrow and day after for Mahavir Jayanti and Good Friday, respectively.
Shares of Ranbaxy Laboratories will stop trading on BSE and NSE from April 6 onwards as the company is getting merged with Sun Pharmaceutical Industries in a USD 4 billion deal.
Sun Pharma has fixed April 7 as the record date for determining the entitlement of Ranbaxy shareholders to the equity shares of the former.
"Following the closure of this transaction, Ranbaxy will be delisted from the Indian Stock Exchanges. Ranbaxy shareholders will receive 0.8 share of Sun Pharma for each share of Ranbaxy," Sun Pharma had said in filing to the BSE last week.
In April 2014, Sun Pharma had announced it would acquire Ranbaxy in an all-stock transaction worth USD 4 billion that includes USD 800 million debt.
The merger would create India's largest and the world's fifth largest drug maker.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 01 2015 | 7:07 PM IST

Next Story